Which has higher valuation & earnings, ORPH or PXS?

Open Orphan has higher revenue and earnings than Provexis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Open Orphan £34.71M 0.00 N/A N/A N/A Provexis £871.27K 25.85 -£619.15K -£0.02 N/A

Is ORPH or PXS more profitable?

Open Orphan has a net margin of 0.00% compared to Provexis' net margin of -69.30%. Open Orphan's return on equity of 0.00% beat Provexis' return on equity. Company Net Margins Return on Equity Return on Assets Open Orphan N/A N/A N/A Provexis -69.30% -49.45% -56.14%

Do analysts rate EAH or PXS?

ECO Animal Health Group currently has a consensus price target of GBX 160, indicating a potential upside of 62.95%. Given ECO Animal Health Group's stronger consensus rating and higher probable upside, equities analysts clearly believe ECO Animal Health Group is more favorable than Provexis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ECO Animal Health Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Provexis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer EAH or PXS?

In the previous week, Provexis had 2 more articles in the media than ECO Animal Health Group. MarketBeat recorded 3 mentions for Provexis and 1 mentions for ECO Animal Health Group. ECO Animal Health Group's average media sentiment score of 0.00 beat Provexis' score of -0.47 indicating that ECO Animal Health Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ECO Animal Health Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Provexis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PXS or STX?

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Provexis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Provexis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate MRK or PXS?

Marks Electrical Group currently has a consensus price target of GBX 52.50, indicating a potential upside of 5.00%. Given Marks Electrical Group's stronger consensus rating and higher possible upside, analysts plainly believe Marks Electrical Group is more favorable than Provexis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marks Electrical Group 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Provexis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, DNL or PXS?

Diurnal Group has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than Diurnal Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diurnal Group £4.68M 0.00 N/A -£8.50 N/A Provexis £871.27K 25.85 -£619.15K -£0.02 N/A

Is DNL or PXS more profitable?

Diurnal Group has a net margin of 0.00% compared to Provexis' net margin of -69.30%. Diurnal Group's return on equity of 0.00% beat Provexis' return on equity. Company Net Margins Return on Equity Return on Assets Diurnal Group N/A N/A N/A Provexis -69.30% -49.45% -56.14%

Provexis (PXS) Competitors

GBX 0.96 +0.02 (+2.13%)

As of 12:10 PM Eastern

Compare

PXS vs. ORPH, EAH, STX, MRK, and DNL

Should you buy Provexis stock or one of its competitors? Provexis's main competitors and comparable companies include Open Orphan (ORPH), ECO Animal Health Group (EAH), Shield Therapeutics (STX), Marks Electrical Group (MRK), and Diurnal Group (DNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Provexis compare to Open Orphan?

Open Orphan (LON:ORPH) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Open Orphan has a net margin of 0.00% compared to Provexis' net margin of -69.30%. Open Orphan's return on equity of 0.00% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
Provexis	-69.30%	-49.45%	-56.14%

Open Orphan has higher revenue and earnings than Provexis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
Provexis	£871.27K	25.85	-£619.15K	-£0.02	N/A

7.9% of Provexis shares are held by institutional investors. 11.8% of Provexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Provexis had 3 more articles in the media than Open Orphan. MarketBeat recorded 3 mentions for Provexis and 0 mentions for Open Orphan. Open Orphan's average media sentiment score of 0.00 beat Provexis' score of -0.47 indicating that Open Orphan is being referred to more favorably in the media.

Company	Overall Sentiment
Open Orphan	Neutral
Provexis	Neutral

Summary

Open Orphan beats Provexis on 6 of the 9 factors compared between the two stocks.

How does Provexis compare to ECO Animal Health Group?

ECO Animal Health Group (LON:EAH) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Provexis had 2 more articles in the media than ECO Animal Health Group. MarketBeat recorded 3 mentions for Provexis and 1 mentions for ECO Animal Health Group. ECO Animal Health Group's average media sentiment score of 0.00 beat Provexis' score of -0.47 indicating that ECO Animal Health Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ECO Animal Health Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Provexis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ECO Animal Health Group has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ECO Animal Health Group	£87.53M	0.75	£1.05M	£3.15	31.17
Provexis	£871.27K	25.85	-£619.15K	-£0.02	N/A

ECO Animal Health Group has a beta of 0.701, meaning that its share price is 30% less volatile than the broader market. Comparatively, Provexis has a beta of 0.662, meaning that its share price is 34% less volatile than the broader market.

ECO Animal Health Group has a net margin of 2.50% compared to Provexis' net margin of -69.30%. ECO Animal Health Group's return on equity of 2.55% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ECO Animal Health Group	2.50%	2.55%	2.14%
Provexis	-69.30%	-49.45%	-56.14%

ECO Animal Health Group currently has a consensus price target of GBX 160, indicating a potential upside of 62.95%. Given ECO Animal Health Group's stronger consensus rating and higher probable upside, equities analysts clearly believe ECO Animal Health Group is more favorable than Provexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ECO Animal Health Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Provexis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

40.6% of ECO Animal Health Group shares are owned by institutional investors. Comparatively, 7.9% of Provexis shares are owned by institutional investors. 11.3% of ECO Animal Health Group shares are owned by company insiders. Comparatively, 11.8% of Provexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ECO Animal Health Group beats Provexis on 13 of the 16 factors compared between the two stocks.

How does Provexis compare to Shield Therapeutics?

Provexis (LON:PXS) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 151.97%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Provexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Provexis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Shield Therapeutics has a net margin of -17.76% compared to Provexis' net margin of -69.30%. Shield Therapeutics' return on equity of 64.57% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Provexis	-69.30%	-49.45%	-56.14%
Shield Therapeutics	-17.76%	64.57%	-47.85%

7.9% of Provexis shares are held by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are held by institutional investors. 11.8% of Provexis shares are held by insiders. Comparatively, 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Provexis has higher earnings, but lower revenue than Shield Therapeutics. Provexis is trading at a lower price-to-earnings ratio than Shield Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provexis	£871.27K	25.85	-£619.15K	-£0.02	N/A
Shield Therapeutics	£58.63M	1.09	-£36.28M	-£1.00	N/A

Provexis has a beta of 0.662, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, meaning that its stock price is 77% more volatile than the broader market.

In the previous week, Provexis had 3 more articles in the media than Shield Therapeutics. MarketBeat recorded 3 mentions for Provexis and 0 mentions for Shield Therapeutics. Shield Therapeutics' average media sentiment score of 0.00 beat Provexis' score of -0.47 indicating that Shield Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Provexis	Neutral
Shield Therapeutics	Neutral

Summary

Shield Therapeutics beats Provexis on 10 of the 16 factors compared between the two stocks.

How does Provexis compare to Marks Electrical Group?

Marks Electrical Group (LON:MRK) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Marks Electrical Group has higher revenue and earnings than Provexis. Marks Electrical Group is trading at a lower price-to-earnings ratio than Provexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marks Electrical Group	£107.93M	0.48	£426.93K	-£0.40	N/A
Provexis	£871.27K	25.85	-£619.15K	-£0.02	N/A

In the previous week, Provexis had 3 more articles in the media than Marks Electrical Group. MarketBeat recorded 3 mentions for Provexis and 0 mentions for Marks Electrical Group. Marks Electrical Group's average media sentiment score of 1.12 beat Provexis' score of -0.47 indicating that Marks Electrical Group is being referred to more favorably in the media.

Company	Overall Sentiment
Marks Electrical Group	Positive
Provexis	Neutral

Marks Electrical Group currently has a consensus price target of GBX 52.50, indicating a potential upside of 5.00%. Given Marks Electrical Group's stronger consensus rating and higher possible upside, analysts plainly believe Marks Electrical Group is more favorable than Provexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marks Electrical Group	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Provexis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Marks Electrical Group has a beta of 0.577, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Provexis has a beta of 0.662, suggesting that its share price is 34% less volatile than the broader market.

Marks Electrical Group has a net margin of -0.39% compared to Provexis' net margin of -69.30%. Marks Electrical Group's return on equity of -4.18% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marks Electrical Group	-0.39%	-4.18%	0.91%
Provexis	-69.30%	-49.45%	-56.14%

10.5% of Marks Electrical Group shares are owned by institutional investors. Comparatively, 7.9% of Provexis shares are owned by institutional investors. 75.4% of Marks Electrical Group shares are owned by company insiders. Comparatively, 11.8% of Provexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Marks Electrical Group beats Provexis on 11 of the 16 factors compared between the two stocks.

How does Provexis compare to Diurnal Group?

Diurnal Group (LON:DNL) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Diurnal Group has a net margin of 0.00% compared to Provexis' net margin of -69.30%. Diurnal Group's return on equity of 0.00% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diurnal Group	N/A	N/A	N/A
Provexis	-69.30%	-49.45%	-56.14%

Diurnal Group has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than Diurnal Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diurnal Group	£4.68M	0.00	N/A	-£8.50	N/A
Provexis	£871.27K	25.85	-£619.15K	-£0.02	N/A

In the previous week, Provexis had 3 more articles in the media than Diurnal Group. MarketBeat recorded 3 mentions for Provexis and 0 mentions for Diurnal Group. Diurnal Group's average media sentiment score of 0.00 beat Provexis' score of -0.47 indicating that Diurnal Group is being referred to more favorably in the media.

Company	Overall Sentiment
Diurnal Group	Neutral
Provexis	Neutral

7.9% of Provexis shares are held by institutional investors. 11.8% of Provexis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Diurnal Group beats Provexis on 6 of the 10 factors compared between the two stocks.

Get Provexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PXS vs. The Competition

Export

Metric	Provexis	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£22.52M	£12.21B	£7.10B	£2.80B
Dividend Yield	5.06%	2.63%	2.53%	6.18%
P/E Ratio	-48.00	797.16	274.61	366.17
Price / Sales	25.85	751.67	601.02	89,425.29
Price / Cash	N/A	81.79	77.38	27.89
Price / Book	111.92	10.47	10.92	6.83
Net Income	-£619.15K	£2.83B	£3.50B	£5.89B
7 Day Performance	18.23%	-1.64%	-2.11%	-0.75%
1 Month Performance	-8.57%	-5.76%	-6.34%	16.84%
1 Year Performance	N/A	-3.79%	8.81%	16.40%

Provexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PXS Provexis	N/A	GBX 0.96 +2.1%	N/A	+53.1%	£22.52M	£871.27K	N/A	4	News Coverage Earnings Report Gap Down
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
EAH ECO Animal Health Group	3.2029 of 5 stars	GBX 98.08 +2.2%	GBX 160 +63.1%	+6.6%	£65.45M	£87.53M	31.14	234
STX Shield Therapeutics	1.1467 of 5 stars	GBX 5.15 +6.2%	GBX 15 +191.3%	-22.6%	£55.10M	£58.63M	N/A	40,000	High Trading Volume
MRK Marks Electrical Group	0.8357 of 5 stars	GBX 46 +1.1%	GBX 52.50 +14.1%	-5.9%	£47.85M	£107.93M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PXS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Provexis (PXS) Competitors

PXS vs. ORPH, EAH, STX, MRK, and DNL

How does Provexis compare to Open Orphan?

Summary

How does Provexis compare to ECO Animal Health Group?

Summary

How does Provexis compare to Shield Therapeutics?

Summary

How does Provexis compare to Marks Electrical Group?

Summary

How does Provexis compare to Diurnal Group?

Summary

Media Sentiment Over Time

PXS vs. The Competition

Provexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Provexis (PXS) Competitors

PXS vs. ORPH, EAH, STX, MRK, and DNL

How does Provexis compare to Open Orphan?

Is ORPH or PXS more profitable?

Which has higher valuation & earnings, ORPH or PXS?

Do insiders & institutionals hold more shares of ORPH or PXS?

Does the media prefer ORPH or PXS?

Summary

How does Provexis compare to ECO Animal Health Group?

Does the media prefer EAH or PXS?

Which has higher valuation & earnings, EAH or PXS?

Which has more volatility & risk, EAH or PXS?

Is EAH or PXS more profitable?

Do analysts rate EAH or PXS?

Do insiders & institutionals believe in EAH or PXS?

Summary

How does Provexis compare to Shield Therapeutics?

Do analysts prefer PXS or STX?

Is PXS or STX more profitable?

Do institutionals & insiders hold more shares of PXS or STX?

Which has higher valuation & earnings, PXS or STX?

Which has more risk and volatility, PXS or STX?

Does the media refer more to PXS or STX?

Summary

How does Provexis compare to Marks Electrical Group?

Which has preferable earnings & valuation, MRK or PXS?

Does the media refer more to MRK or PXS?

Do analysts rate MRK or PXS?

Which has more volatility and risk, MRK or PXS?

Is MRK or PXS more profitable?

Do insiders & institutionals have more ownership in MRK or PXS?

Summary

How does Provexis compare to Diurnal Group?

Is DNL or PXS more profitable?

Which has higher valuation & earnings, DNL or PXS?

Does the media prefer DNL or PXS?

Do institutionals and insiders believe in DNL or PXS?

Summary

Media Sentiment Over Time

PXS vs. The Competition

Provexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools